Biotech, FDA, Tysabri

Biogen Reports 10th PML Case in Tysabri Patient

Roxanne Palmer 6/29/09

Biogen Idec (NASDAQ:BIIB) reported a tenth case of a serious brain infection in a patient taking Tysabri, the Cambridge, MA-based company’s drug for multiple sclerosis and Crohn’s disease. The news was disclosed late last Friday on the company’s website (pdf here). Luke wrote back in December about the history of Tysabri, which was pulled from the market in February 2005 after two cases of PML and returned to the market under a strict monitoring program in July 2006.

Roxanne is an intern in Xconomy's Boston office. You can reach her at rpalmer@xconomy.com.